|Bid||73.31 x 500|
|Ask||73.32 x 300|
|Day's Range||72.65 - 73.44|
|52 Week Range||63.76 - 82.10|
|PE Ratio (TTM)||7.76|
|Dividend & Yield||2.08 (2.88%)|
|1y Target Est||N/A|
Here is a look at four biotech stocks including Gilead (GILD) that topped estimates in Q2 and are witnessing upward estimate revisions for the current year.
Alexion Pharmaceuticals (ALXN) announced that the European Commission (EC) approved a label expansion of lead drug Soliris which should further boost sales.
There's still plenty of value to be found in this overheated market from the likes of Gilead Sciences, IBM, and Ambarella.